ADvantage Therapeutics, Inc. Welcomes Dr. William A. Haseltine as Strategic Advisor to Drive Innovation in Alzheimer's Disease Research and Anti-aging Therapies such as Klotho Protein Supplementation to Extend Healthy Human Lifespan
09. September 2024 10:01 ET
|
ADvantage Therapeutics, Inc.
MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc., a leading clinical-stage biotechnology company dedicated to the advancement of innovative therapies for Alzheimer's disease,...
ADvantage Therapeutics Announces Breakthrough Findings in Alzheimer's Disease Treatment: AD04TM shows immediate symptomatic and disease-modifying properties
30. Juli 2024 12:04 ET
|
ADvantage Therapeutics, Inc.
PHILADELPHIA, July 30, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics today announced groundbreaking results from a study on AD04™, a novel therapeutic candidate for Alzheimer's disease. Scientists...
Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics
05. Februar 2024 09:41 ET
|
Advantage Therapeutics Inc.
BOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging,...
ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease
27. November 2023 08:45 ET
|
Advantage Therapeutics Inc.
MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of...
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia
20. Juni 2023 09:00 ET
|
Advantage Therapeutics Inc.
MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics
24. März 2023 08:45 ET
|
Advantage Therapeutics Inc.
BOCA RATON, Fla. and VIENNA, Austria, March 24, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative...
ADvantage Therapeutics Developing Therapies to Treat Neurodegenerative Conditions with Focus on Alzheimer’s Disease
15. März 2023 10:18 ET
|
Advantage Therapeutics Inc.
MIAMI, March 15, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...